Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

Is Spectrum undervalued? I have to say yes. I just looked at something sent to me from Seeking Alpha about Keryx

Keryx Biopharma +5.4% on strong preliminary numbers
Jan. 9, 2017 11:34 AM ET|About: Keryx Biopharmaceuticals... (KERX)|By: Stephen Alpher, SA News Editor
Q4 prescription demand was about 8.7K prescriptions, which included 4.5K for December, the first full month of sales post resupply of Auryxia. The FDA has also approved Patheon's manufacturing facility in France which will supply Auryxia to the U.S.
Keryx (KERX +5.4%) expects Q4 revenues of about $9.5M vs. $5.8M a year earlier. Full-year revenues should foot to $31.9M vs. $13.7M in 2015.
Cash and cash equivalents totaled about $112.1M at year-end.

Keryx MC is at 673M vs 372M for SPPI. They expect revenue in Q4 at 9.5M vs 5.8 last year whereas I see SPPI revenue at potentially over 35M in Q4 (Yahoo analyst figures be damned at 30.3M). They have cash at 112M vs 172M for SPPI at end of Q3. Regarding the future, I’m too lazy/lack of time to check into Keryx now but I will pay attention to them at their quarterly but SPPI does have growing revenue potential in Evomela, incremental increases of their other drugs and has pivotal P3 studies for Rolontis and a P2 study for Poziotinib. SPPI seems undervalued to me.

To be continued after the next quarterly meetings…